The Safety and Efficacy of SYD-101 in Children With Myopia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

852

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

May 2, 2024

Study Completion Date

May 31, 2025

Conditions
NearsightednessNear SightednessNear-sightedness
Interventions
DRUG

SYD-101 Dose 1

Sterile topical ophthalmic solution

DRUG

SYD-101 Dose 2

Sterile topical ophthalmic solution

DRUG

Vehicle

Sterile topical ophthalmic solution without active ingredient

Trial Locations (47)

1140

Site 205, Vienna

4021

Site 203, Linz

8036

Site 204, Graz

14209

Site 127, Buffalo

16066

Site 128, Cranberry Township

23452

Site 113, Virginia Beach

27517

Site 117, Chapel Hill

27603

Site 121, Raleigh

29425

Site 108, Charleston

30060

Site 124, Marietta

33182

Site 119, Sweetwater

33309

Site 122, Fort Lauderdale

33321

Site 120, Tamarac

33477

Site 109, Jupiter

46202

Site 135, Indianapolis

46321

Site 131, Munster

58103

Site 105, Fargo

60091

Site 106, Wilmette

60616

Site 116, Chicago

63090

Site 114, Washington

66762

Site 137, Pittsburg

77380

Site 115, The Woodlands

78215

Site 142, San Antonio

78240

Site 101, San Antonio

78734

Site 126, Lakeway

80528

Site 100, Fort Collins

80920

Site 130, Colorado Springs

84403

Site 149, Ogden

84405

Site 140, Ogden

87109

Site 139, Albuquerque

89052

Site 132, Henderson

91105

Site 144, Pasadena

91108

Site 200, Trenčín

91706

Site 143, Irwindale

92127

Site 148, San Diego

92131

Site 104, San Diego

93110

Site 110, Santa Barbara

94087

Site 133, Sunnyvale

97223

Site 147, Tigard

97504

Site 111, Medford

06810

Site 102, Danbury

06708

Site 150, Waterbury

04401

Site 138, Bangor

02111

Site 123, Boston

19004-1108

Sie 136, Bala-Cynwyd

833 40

Site 202, Bratislava

075 01

Site 201, Trebišov

All Listed Sponsors
lead

Sydnexis, Inc.

INDUSTRY